The blood test was found to detect colorectal cancer with 92 percent sensitivity and 97 percent specificity. It also was shown to have 89 percent sensitivity and 97 percent specificity detecting early-stage cancer. The test uses single target sequence analyses of multiomics markers, computational biology and machine learning.
“We have built a test that can ‘read’ cancer’s tissue-specific signal in blood on a fragment level,” Universal Diagnostics’ managing director, Christian Hense, said. “We know that if we can detect cancer early, or identify pre-cancer stage patients before they develop cancer, the survival rates increase exponentially.”
Universal Diagnostics focuses on identifying early-stage cancer and is developing its Signal-X platform to detect multiple cancer types. Its Signal-C platform focuses on colorectal cancer and adenomatous polyps.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.